Ovarian cancers with germline or somatic mutation of BRCA1 or BRCA2, mutation of RAD51C or RAD51D, methylation of BRCA1, or high LOH have all been reported to respond to PARP inhibition (Audeh et al., 2010; Wang et al., 2012; Ledermann J. et al., 2014; Kondrashova et al., 2017; Swisher et al., 2017; Moore et al., 2018). Here, BRCA2 is linked to ovarian cancer.